<DOC>
	<DOCNO>NCT02976129</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety V565 participant active Crohn 's Disease .</brief_summary>
	<brief_title>A Six Week Efficacy , Safety Tolerability Study V565 Crohn 's Disease</brief_title>
	<detailed_description>This study multiple-site , double-blind , placebo-controlled , parallel-group study approximately 126 subject confirm diagnosis CD least three month CD involve ileum and/or colon . Following screening period 28 day , subject randomly allocate one two treatment arm : either V565 placebo use 2:1 active : placebo ratio treatment period 6 week . Subjects treat study drug add-on permit stable medication already take CD .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>History Crohn 's Disease least 3 month duration prior screen CDAI score ≥220 ≤450 screen CRP ≥5 mg/L ( , CRP normal , FCP ≥250 µg/g ) screen Permitted CD medication regimen expect remain stable period study Previous lack response current contraindication antiTNFα agent Certain complication Crohn 's Disease would make hard ass response study drug Known history suspicion IBD Crohn 's disease History TB latent TB infection treat Any significant illness condition would preclude effective participation study GI infection demonstrate presence enteric pathogens Pregnant lactate woman Abdominal surgery previous 6 month Unsuitable inclusion study opinion investigator sponsor reason may compromise subject 's safety confound data interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>